The team from Kolkata's CSIR-Indian Institute of Chemical Biology, Republic of Korea's Institute for Basic Science (IBS), Kolkata's Vidyasagar College and the Institute of Postgraduate Medical Education and Research (IPGMER) here has in a recent study answered a long standing question as to why diabetics have more amount of an enzyme called dipeptidyl peptidase
4 or DPP4 in their blood.
It increases the physiological concentration of glucagon like peptide GLP-1 and glucose dependent insulinotropic polypeptide (GIP) in body by inhibiting the enzyme dipeptidyl peptidase
-IV (DPP-4) with well tolerated profile, no risk of weight gain and hypoglycemia.
Inhibitors of dipeptidyl peptidase
IV: a novel approach for the prevention and treatment of type 2 diabetes?
However, the available data on the inhibition of dipeptidyl peptidase
in RA suggest that we should be careful in terms of the use of DPP-4 inhibitors in the treatment of diabetic patients with RA.
IV inhibitors for the treatment of diabetes.
Inhibition of dipeptidyl peptidase
IV (DPP-IV) is one of the mechanisms explaining the hypoglycemic effect of berberine.
These nine articles describe some of the work being done to differentiate markers and use their presence to detect and treat a range of cancers, addressing the characterization of breast cancer subtypes in a large retrospective study, intraocular lymphoma markers, polymorphisms in genes associated with certain T-cell lymphomas, tumor antigens that are markers of minimal residual disease in acute myeloid leukemia, thyroid tumor markers, activity and expression of dipeptidyl peptidase
IV and cathepsin H in human cutaneous melanoma compared to other common cancers, melanoma inhibitory activity as a serological marker in metastic melanoma, and the promise (or myth) of the tumor necrosis factor alpha receptors p55 and p75 in ovarian cancer detection.
Both compounds inhibit an enzyme called dipeptidyl peptidase
4 (DPP-4), which usually controls the body's production of a hormone, called GLP1.
Tokyo, Japan, June 15, 2006 - (JCN) - Ono Pharmaceutical and Banyu Pharmaceutical have obtained positive results in the recent clinical trials of sitagliptin, a dipeptidyl peptidase
IV (DPP4) inhibitor.
OSI) Prosidion's lead compound, PSN9301, is a Dipeptidyl Peptidase
IV (DPIV) inhibitor currently in Phase II clinical trials.
The rights to the dipeptidyl peptidase
IV inhibitors had earlier been shared between PPD and Syrrx Inc.
Despite this change, HAP is an active protease with distinct properties, and together with a series of cysteine and metallo-proteases and a dipeptidyl peptidase
, provides attractive focus for antimalarial drug development.